Ginkgo Bioworks Holdings, Inc. DNA
10.25 USD -1.76 (-14.65%)
At closeNov 12, 2026, 4:00 AM EST
10.30 +0.05 +0.49%
Pre-market · Nov 12, 4:00 AM ET
10.25 Day range 12.78
5.37 52-week range 18.22
- YTD
- +23.35%
- 1 year
- +21.16%
News
globenewswire.com Rakovina Therapeutics Secures Exclusive Worldwide Licence to Artemis.AI™ Platform for DNA-Damage Response Oncology Drug Discovery Perpetual, royalty-free, exclusive licence for DDR oncology including all future platform improvements, in exchange for C$1.0 million in Rakovina shares Perpetual, royalty-free, exclusive licence for…
fool.com Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors Novo Nordisk selected Ginkgo to build an autonomous research laboratory. Ginkgo ended the third quarter with $285 million in cash.
marketbeat.com Ginkgo Bioworks Q3 Earnings Call Highlights Ginkgo Bioworks NYSE: DNA reported lower third-quarter revenue but narrowed its loss as restructuring-related expense cuts took hold, while executives highlighted new customers for its autonomous…
seekingalpha.com Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript
businesswire.com Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the third quarter of 2026 that ended September 30, 2026. The update, including a webcast…
benzinga.com TD Cowen Maintains Hold on Ginkgo Bioworks Holdings, Raises Price Target to $11 TD Cowen analyst Brendan Smith maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Hold and raises the price target from $9 to $11.